Does testosterone therapy increase CV risk? 

Testosterone therapy is widely prescribed for older men experiencing symptoms of hypogonadism, despite lacking robust data on cardiovascular (CV) safety. The American Food and Drug Administration mandated a trial to assess this risk due to sparse and inconclusive evidence. In this short video, Prof Michael Lincoff, Vice Chairman of the Robert and Suzanne Tomsich Department of CV Medicine and an interventional cardiologist in the Sydell and Arnold Miller Family Heart, Vascular and Thoracic Institute at Cleveland Clinic, gives a short overview of the key findings of the trial entitled A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men (TRAVERSE). TRAVERSE was the largest testosterone trial, focused on high-risk patients with stringent criteria for hypogonadism, and meticulously tracked CV endpoints.

Testosterone therapy 101 

The international Andrology Research Academy provides a forum for educational exchange of cutting-edge research in andrology. The academy recently introduced a series of educational videos addressing topics related to testosterone deficiency and its treatment. These videos have been curated by Prof Abraham Morgentaler, the founder of Testosterone for Life (T4L). Prof Morgentaler, a trailblazer in the field, has dedicated his career to dispelling myths and misconceptions surrounding testosterone use. Through T4L, his mission has been to offer trustworthy and current educational resources.

For access to all these videos, please register to the free educational platform: https://live.arealive.org/webinars/public/index.html#login

Topics include: 

 

1. Transformative insights from the landmark TRAVERSE trial: A new era in T Therapy -  https://live.arealive.org/webinars/public/index.html#home
2. The importance of testosterone in men's health https://live.arealive.org/webinars/public/index.html#webinar&id=course1 
3. History of testosterone therapy: Where have we been and where are we going? 
   https://live.arealive.org/webinars/public/index.html#webinar&id=course2  
4. What's in a name: Understanding the terminology 
   https://live.arealive.org/webinars/public/index.html#webinar&id=course3 
5. Is it low testosterone or is it natural ageing? 
   https://live.arealive.org/webinars/public/index.html#webinar&id=course4  
6. Impact of testosterone deficiency and testosterone therapy on human health 
   https://live.arealive.org/webinars/public/index.html#webinar&id=course5  
7. Navigating a sea of guidelines: What you need to know 
   https://live.arealive.org/webinars/public/index.html#webinar&id=course6  
8. Who is a candidate for testosterone deficiency
   https://live.arealive.org/webinars/public/index.html#webinar&id=course7  
9. How to treat
   https://live.arealive.org/webinars/public/index.html#webinar&id=course8  
10. Prostate cancer and BPH: What's the truth
    https://live.arealive.org/webinars/public/index.html#webinar&id=course9  
11. Testosterone deficiency and testosterone therapy: Addressing cardiovascular disease risks
    https://live.arealive.org/webinars/public/index.html#webinar&id=course10  
12. Other risks and their management
    https://live.arealive.org/webinars/public/index.html#webinar&id=course11  
13. Testosterone and fertility
    https://live.arealive.org/webinars/public/index.html#webinar&id=course12  
14.  Management of complex clinical cases
    https://live.arealive.org/webinars/public/index.html#webinar&id=course13  
15. How to evaluate and treat men with erectile dysfunction: Pills, injections, surgery, and more
    https://live.arealive.org/webinars/public/index.html#webinar&id=course14  
16. New and cutting-edge treatments for ED: Low intensity shock wave therapy and PRP
    https://live.arealive.org/webinars/public/index.html#webinar&id=course15